All In Biotech

Drug Trial Radar · NCT03573882

Study to Assess the Effect of Long-term Treatment With Voxelotor in Participants Who Have Completed Treatment in Study GBT440-031

An Open Label Extension Study of Voxelotor (GBT440) Administered Orally to Participants With Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials

Last checked: Nov 20, 2026Latest source record: Nov 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

TerminatedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Terminated

Enrollment

179

Actual

Start

Jun 6, 2018

Primary completion

Nov 12, 2024

Study completion Nov 12, 2024

Sponsor

Lead sponsor
PfizerPfizer (PFE)
Sponsor type
Industry
First posted
Jun 29, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Open Label Extension Study of Voxelotor Clinical Trial Participants with Sickle Cell Disease Who Participated in Voxelotor Clinical Trials

Conditions

  • Sickle Cell Disease

Interventions

  • VoxelotorDrug

    300mg or 500mg Tablet, Oral, With or Without Food

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Sickle Cell Disease (SCD)-Related Treatment Emergent Adverse Events (TEAEs)Time frame: From date of informed consent up to 28 days after last dose of study drug (maximum up to 300.7 weeks)
  2. Number of Participants With Non- SCD-Related TEAEsTime frame: From date of informed consent up to 28 days after last dose of study drug (maximum up to 300.7 weeks)
  3. Number of Participants With SCD-Related Treatment Emergent Serious Adverse Events (TESAEs)Time frame: From date of informed consent up to 28 days after last dose of study drug (maximum up to 300.7 weeks)
  4. Number of Participants With Non-SCD-Related TESAEsTime frame: From date of informed consent up to 28 days after last dose of study drug (maximum up to 300.7 weeks)
  5. Annualized Incidence Rate (Events Per Person Years) of SCD-Related ComplicationsTime frame: From date of informed consent up to earlier of 28 days after last dose of study drug or end of study date (maximum up to 300.7 weeks)
  6. Annualized Incidence Rate (VOC Events Per Person Years) of On-Treatment Vaso-occlusive Crisis (VOCs)Time frame: From date of informed consent to last dose of study drug (maximum up to 296.7 weeks)

Locations

60 sites in 11 countries. Site status is shown where the registry gives one.

  • Arkansas Primary Care Clinic, PA

    Little Rock, Arkansas

  • UCSF Benioff Children's Hospital Oakland

    Oakland, California

  • Jackson Memorial Hospital (Investigational Drug Services)

    Miami, Florida

  • Jackson Memorial Hospital

    Miami, Florida

  • University of Miami Hospital & Clinics/SCCC, Research Pharmacy (Investigational Drug Services)

    Miami, Florida

  • University of Miami

    Miami, Florida

  • Children's Healthcare of Atlanta - Scottish Rite

    Atlanta, Georgia

  • University of Illinois at Chicago Clinical Research Center

    Chicago, Illinois

  • University of Illinois Hospital and Health Science System

    Chicago, Illinois

  • Indiana Hemophilia and Thrombosis Center

    Indianapolis, Indiana

  • St. Jude Affiliate Clinic Baton Rouge

    Baton Rouge, Louisiana

  • Our Lady of the Lake Physician Group-Medical Oncology

    Baton Rouge, Louisiana

  • University Medical Center New Orleans

    New Orleans, Louisiana

  • Johns Hopkins University/Sickle Cell Infusion Center

    Baltimore, Maryland

  • Brigham and Women's Hospital

    Boston, Massachusetts

  • Brigham and Women's Hospital Research Pharmacy

    Boston, Massachusetts

  • Dana Farber Cancer Institute

    Boston, Massachusetts

  • Children's Hospital of Michigan

    Detroit, Michigan

  • Newark Beth Israel Medical Center

    Newark, New Jersey

  • Columbia University Medical Center - Herbert Irving Pavilion

    New York, New York

  • Montefiore - Einstein Center for Cancer Care

    The Bronx, New York

  • UNC Hospitals

    Chapel Hill, North Carolina

  • Clinical and Translational Research Center (CTRC)

    Chapel Hill, North Carolina

  • Duke University Medical Center

    Durham, North Carolina

  • Investigational Drug Service, Duke University Hospital

    Durham, North Carolina

  • Lynn Health Science Institute

    Oklahoma City, Oklahoma

  • Thomas Jefferson University

    Philadelphia, Pennsylvania

  • University of Pittsburgh Medical Center (UPMC)

    Pittsburgh, Pennsylvania

  • Medical University of South Carolina - Comprehensive Sickle Cell Clinic

    Charleston, South Carolina

  • Medical University of South Carolina: Investigational Drug Services Pharmacy

    Charleston, South Carolina

  • Methodist Comprehensive Sickle Cell Clinic

    Memphis, Tennessee

  • Texas Children's Hospital - Investigational Pharmacy

    Houston, Texas

  • Texas Children's Hospital

    Houston, Texas

  • Clinical Research Services Unit- Virginia Commonwealth University

    Richmond, Virginia

  • Toronto General Hospital-University Health Network

    Toronto, Ontario, Canada

  • Alexandria Clinical Research Center, Faculty of Medicine, Alexandria University

    Alexandria, Egypt

  • Alexandria Clinical Research Center, Faculty of Medicine

    Alexandria, Egypt

  • Zagazig University Hospital

    Alsharkia, Egypt

  • Abu El Rich Hospital,Cairo University Hospital

    Cairo, Egypt

  • Ain Shams University Hospital

    Cairo, Egypt

Showing 40 of 60 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.